Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Oncologist - United States
doi 10.1634/theoncologist.2018-0839
Full Text
Open PDFAbstract
Available in full text
Date
March 22, 2019
Authors
Publisher
Alphamed Press